Back to Search Start Over

The role of complex IV activity in the axonal response of mitochondria to demyelination in experimental disease models of multiple sclerosis

Authors :
Graham R. Campbell
Arpan R Metha
Yolanda S. Kap
Daniel Altman
Chao Zhao
David Baker
Stephen M. Anderton
Siddharthan Chandran
Katie McGill
Kenneth Smith
Bruce D. Trapp
Hans Lassmann
Jon D. Laman
Bert A t'Hart
Moses Rodriguez
Don J. Mahad
Stephanie E J Zandee
Robin J.M. Franklin
Sarah Al-Azki
Simon Licht-Mayer
Markus Kipp
Alex Symonds
Gareth Pryce
Publication Year :
2021
Publisher :
Cold Spring Harbor Laboratory, 2021.

Abstract

Axon loss is a cardinal neuropathological feature of multiple sclerosis (MS). Axonal injury in MS and experimental disease models is most frequently detected in acutely demyelinating regions. Furthermore, acute axonal injury consistently correlates with the extent of inflammatory demyelination. Following lysolecithin-induced demyelination, we recently reported a compensatory response in neurons, where mitochondria move from the cell body to the acutely demyelinated axon and increase the mitochondrial content. We termed this energetics phenomenon, that is also evident in MS, the axonal response of mitochondria to demyelination (ARMD). In the present study, we assessed axonal mitochondrial content as well as axonal mitochondrial respiratory chain complex IV activity (COX) of axons and related these to axonal injury in nine different experimental disease models. We consistently found ARMD in all experimental disease models. However, the increase in mitochondrial content within demyelinated axons was not always accompanied by a proportionate increase in COX activity, particularly in experimental autoimmune encephalomyelitis (EAE). Axonal COX activity inversely correlated with the extent of axonal injury in experimental disease models. Our findings indicate that ARMD is a consistent and prominent finding and emphasises the need to preserve axonal mitochondrial COX activity in inflammatory demyelination, paving the way for the development of novel neuroprotective therapies.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........5d200d032d9cb001e6fcf387053783b5
Full Text :
https://doi.org/10.1101/2021.09.27.461926